Understanding the warburg effect: The metabolic requirements of cell proliferation

Science

Volumn 324, Issue 5930, 2009, Pages 1029-1033

  Heiden, Matthew G Vander ^a,b   Cantley, Lewis C ^b   Thompson, Craig B ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; LIPID; NUCLEOTIDE;

CYTOLOGY; METABOLISM;

BIOMASS; CANCER CELL; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL TRANSPORT; GLYCOLYSIS; GROWTH REGULATION; HUMAN; MAMMAL CELL; METABOLIC REGULATION; MUTATION; NUTRIENT UPTAKE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AEROBIOSIS; AMINO ACIDS; ANIMALS; CELL PROLIFERATION; GLUCOSE; GLYCOLYSIS; HUMANS; LIPIDS; METABOLIC NETWORKS AND PATHWAYS; MUTATION; NEOPLASMS; NUCLEOTIDES; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 66249108601     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1160809     Document Type: Review

References (49)

1. P. P. Hsu, D. M. Sabatini, Cell 134, 703 (2008).
2. R. J. Deberardinis, J. J. Lum, G. Hatzivassiliou, C. B. Thompson, Cell Metab. 7, 11 (2008).
3. O. Warburg, K. Posener, E. Negelein, Biochem. Z. 152, 319 (1924).
4. O. Warburg, Science 123, 309 (1956).
5. S. Weinhouse, Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 87, 115 (1976).
6. V. R. Fantin, J. St-Pierre, P. Leder, Cancer Cell 9, 425 (2006).
7. R. Moreno-Sanchez, S. Rodriguez-Enriquez, A. Marin-Hernandez, E. Saavedra, FEBS J. 274, 1393 (2007).
8. A. L. Lehninger, D. L. Nelson, M. M. Cox, Principles of Biochemistry (Worth, New York, ed. 2, 1993).
9. H. R. Christofk et al., Nature 452, 230 (2008).
10. D. S. Izyumov et al., Biochim. Biophys. Acta 1658, 141 (2004).
11. M. G. Vander Heiden, N. S. Chandel, P. T. Schumacker, C. B. Thompson, Mol. Cell 3, 159 (1999).
12. R. J. Shaw et al., Proc. Natl. Acad. Sci. U.S.A. 101, 3329 (2004).
13. J. J. Lum et al., Cell 120, 237 (2005).
14. D. G. Hardie, Nat. Rev. Mol. Cell Biol. 8, 774 (2007).
15. Possibly up to four NADPH molecules per glucose can be produced if the products of the pentose phosphate shunt are metabolized via the TCA cycle and malic enzyme or cytosolic isocitrate dehydrogenase 1 (IDH1) to generate two additional NADPH molecules.
16. R. J. DeBerardinis et al., Proc. Natl. Acad. Sci. U.S.A. 104, 19345 (2007).
17. H. R. Christofk, M. G. Vander Heiden, N. Wu, J. M. Asara, L. C. Cantley, Nature 452, 181 (2008).
18. G. Hatzivassiliou et al., Cancer Cell 8, 311 (2005).
19. P. Sonveaux et al., J. Clin. Invest. 118, 3930 (2008).
20. M. Buzzai et al., Oncogene 24, 4165 (2005).
21. J. A. Engelman et al., Nat. Med. 14, 1351 (2008).
22. M. G. Vander Heiden et al., Mol. Cell. Biol. 21, 5899 (2001).
23. S. Ben-Haim, P. Ell, J. Nucl. Med. 50, 88 (2009).
24. B. E. Baysal et al., Science 287, 848 (2000).
25. P. J. Pollard, N. C. Wortham, I. P. Tomlinson, Ann. Med. 35, 634 (2003).
26. M. A. Selak et al., Cancer Cell 7, 77 (2005).
27. D. W. Parsons et al., Science 321, 1807 (2008).
28. F. E. Bleeker et al., Hum. Mutat. 30, 7 (2009).
29. H. Yan et al., N. Engl. J. Med. 360, 765 (2009).
30. C. B. Thompson, N. Engl. J. Med. 360, 813 (2009).
31. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, Y. Lazebnik, J. Cell Biol. 178, 93 (2007).
32. D. R. Wise et al., Proc. Natl. Acad. Sci. U.S.A. 105, 18782 (2008).
33. P. Gao et al., Nature 458, 762 (2009).
34. K. Bensaad et al., Cell 126, 107 (2006).
35. F. Chiaradonna et al., Oncogene 25, 5391 (2006).
36. M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, S. W. Lowe, Cell 88, 593 (1997).
37. D. Granot, M. Snyder, Proc. Natl. Acad. Sci. U.S.A. 88, 5724 (1991).
38. Z. Chen, E. A. Odstrcil, B. P. Tu, S. L. McKnight, Science 316, 1916 (2007).
39. R. A. Gatenby, R. J. Gillies, Nat. Rev. Cancer 4, 891 (2004).
40. S. Gottschalk, N. Anderson, C. Hainz, S. G. Eckhardt, N. J. Serkova, Clin. Cancer Res. 10, 6661 (2004).
41. R. L. Elstrom et al., Cancer Res. 64, 3892 (2004).
42. K. B. Nolop et al., Cancer 60, 2682 (1987).
43. H. Kondoh et al., Antioxid. Redox Signal. 9, 293 (2007).
44. J. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, A. D. Morris, BMJ 330, 1304 (2005).
45. E. E. Calle, R. Kaaks, Nat. Rev. Cancer 4, 579 (2004).
46. M. Pollak, Nat. Rev. Cancer 8, 915 (2008).
47. M. R. El-Maghrabi, S. J. Pilkis, J. Cell. Biochem. 26, 1 (1984).
48. We thank A. Van den Abbeele (Department of Imaging, Dana-Farber Cancer Institute, Boston) for the FDG-PET image. We also thank K. D. Courtney, A. J. Shaywitz, and K. D. Swanson for thoughtful discussions and critical reading of the manuscript and the Damon Runyon Cancer Research Foundation for support (to M.G.V.H.). M.G.V.H. receives grant support from the National Cancer Institute (NCI) and NIH; L.C.C. receives grant support from the NIH;
49. and C.B.T. receives grant support from the NCI, NIH, and Abramson Family Cancer Research Institute to study aspects of cancer cell metabolism. M.G.V.H., L.C.C., and C.B.T. hold patents related to the targeting of cancer cell metabolism and have financial interests in Agios Pharmaceuticals, a company that seeks to exploit alterations in cancer metabolism for novel therapeutics.